2009;158:554 61. S4.4.2-51. Schulman-Marcus J, Valenti V, Hartaigh BO, et al. Prognostic util- ity of coronary artery calcium scoring in active smokers: a 15-year follow-up study. Int J Cardiol. 2014;177:581 3. S4.4.2 52. Valenti V, Hartaigh BO, Cho I, et al. Absence of coronary artery cal- cium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging 2016;9:e003528. S4.4.2 53. Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a family history of pre- mature coronary heart disease: results from Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015:8;e003186. S4.4.2-54. Sharp Collaborative Group null. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lower- ing low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. Am Heart J. 2010;160:785 94; e10. S4.4.2-55. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351 64. S4.4.2-56. Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipid- emia. Ann Intern Med. 1995;123:493 9. S4.4.2-57. Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314:142 50. S4.4.2-58. Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292 302. S4.4.2-59. Navar-Boggan AM, Peterson ED, D Agostino RB Sr, et al. Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. J Am Coll Cardiol. 2015;65:1633 9. S4.4.2-60. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. 